|drug718||Camostat Mesylate Wiki||1.00|
|drug727||Capillary and salivary sampling Wiki||1.00|
|drug3371||Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling. Wiki||0.71|
|D020141||Hemostatic Disorders NIH||0.27|
|D001778||Blood Coagulation Disorders NIH||0.27|
There is one clinical trial.
The primary aim of this study is to determine whether Camostat mesylate reduces SARS-COV-2 associated coagulopathy. Additional aims are to determine the effect of Camostat mesylate on SARS-COV-2 associated myocardial injury, to assess duration of hypoxia or intubation, to evaluate the length of intensive care unit and hospital stay, and assess mortality rates.
Description: The sum percent change in D-Dimer over 7 days will be compared to day 1Measure: Percent change in plasma D-Dimer Time: 7 days
Description: The first assessment on mortality and complications will be carried out 3 months after the start of the study.Measure: Overall Safety and adverse event Time: 3 months
Description: Percent change in fibrinogen over 7 days compared to day 1Measure: Change in plasma Fibrinogen levels Time: 7 days
Description: Percent change in troponin over 7 days compared to day 1Measure: Change in plasma troponin Time: 7 days
Description: New onset cardiomyopathy defined by a reduction of EF by greater than 10% or less than 45% will be measuredMeasure: New onset cardiomyopathy Time: 7 days
Description: Days with hypoxia (Room Air O2 Sat<93%) or days intubatedMeasure: Duration of intubation Time: 7 days
Description: The number of days in the intensive care unitMeasure: Length of stay in the intensive care unit Time: 28 days
Description: The number of days since admission to dischargeMeasure: Time to discharge from hospital Time: 30 days
Description: The ocurrence of major adverse cardiovascular events (MACE): MI, stroke, CHF, PCI, death from cardiovascular disease will be studied.Measure: Occurrence of major adverse cardiovascular events Time: 7 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports